Does Rallies show 13F holders for STRO?

Yes. Rallies tracks hedge fund and 13F ownership data for STRO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is STRO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for STRO. It does not provide personalized investment advice.

STRO (Sutro Biopharma, Inc.) Stock Analysis - Hedge Fund Holdings

Sutro Biopharma, Inc. (STRO) is a publicly traded Healthcare sector company. As of May 21, 2026, STRO trades at $30.52 with a market cap of $571.35M and a P/E ratio of -1.26. STRO moved -1.80% today. Year to date, STRO is +186.38%; over the trailing twelve months it is +246.00%. Its 52-week range spans $5.23 to $46.00. Analyst consensus is strong buy with an average price target of $47.50. Rallies surfaces STRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns STRO stock?

Hedge funds tracked by Rallies that own STRO include Orbimed Advisors, Pentwater Capital, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Sutro Biopharma, Inc..

STRO Key Metrics

Key financial metrics for STRO
Metric	Value
Price	$30.52
Market Cap	$571.35M
P/E Ratio	-1.26
EPS	$-24.53
Dividend Yield	0.00%
52-Week High	$46.00
52-Week Low	$5.23
Volume	120
Avg Volume	0
Revenue (TTM)	$99.61M
Net Income	$-153.60M
Gross Margin	0.00%

Top Hedge Funds Holding STRO

Orbimed Advisors holds 801.14K shares of STRO, changed +0.00% as of Mar 31, 2026.
Pentwater Capital holds 450.00K shares of STRO, changed +0.00% as of Dec 31, 2023.
Panagora Asset holds 140.36K shares of STRO, changed -1.28% as of Mar 31, 2025.

Latest STRO News

Sutro Biopharma Plans IND Submissions for Two ADCs, Holds $202.6M Cash — May 14, 2026
Sutro Biopharma Doses Third STRO-004 Cohort, Raises $110M to Extend Cash to 2Q 2028 — Mar 23, 2026
Sutro Biopharma Prices $110M Stock Offering at $13.98 Per Share — Feb 10, 2026

Recent STRO Insider Trades

Gerber Hans-Peter bought 17.00K (~$13.61K) on Oct 15, 2025.
Chow Gregory K. bought 19.75K (~$16.00K) on Oct 15, 2025.
Chung Jane bought 12.50K (~$10.01K) on Oct 15, 2025.

STRO Analyst Consensus

9 analysts cover STRO: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $47.50.

Common questions about STRO

Who owns STRO stock?: Hedge funds tracked by Rallies that own STRO include Orbimed Advisors, Pentwater Capital, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Sutro Biopharma, Inc..
Does Rallies show 13F holders for STRO?: Yes. Rallies tracks hedge fund and 13F ownership data for STRO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is STRO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for STRO. It does not provide personalized investment advice.